GuideWhat is ergothioneine?Definition, transporter, food, human evidence and open questionsGuideBenefits and researchA claim-by-claim view of the evidenceResearchHealthy agingHuman and preclinical evidence for healthy-aging questionsResearchCognitive healthTrials and observational cognition researchGuideFood sourcesMushrooms and other dietary sourcesSafetyDosageResearch doses, commercial amounts and uncertaintySafetySafety and side effectsHuman safety evidence and unknownsBuyer guideSupplementsA neutral orientation to supplement formsBuyer guideHow to chooseTesting, source, COAs and cost per mg

Structured research library

Complete Ergothioneine Study Database

Search verified records by design and topic. Every record exposes the finding, limitation and primary source.

6 verified records5 human records0 fabricated citations

Showing 6 verified research records

Human RCT2024n = 19

Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study

Intervention
25 mg, three times weekly
Duration
1 year

Finding: The ergothioneine group improved on a learning assessment and showed a different neurofilament-light trajectory than placebo; routine blood, kidney and liver safety markers did not change.

Important limitation: Very small pilot sample; exploratory outcomes; not adequate to establish prevention or treatment of cognitive decline.

PubMed ↗Our interpretation →
Human RCT2025n = See full text

Estimation and Validation of an Effective Ergothioneine Dose for Improved Sleep Quality Using a Physiologically Based Pharmacokinetic Model

Intervention
5 or 10 mg/day in dose modeling; 8 mg/day vs placebo in validation
Duration
8–16 weeks

Finding: The 8 mg/day validation study reported a statistically significant improvement in subjective sleep quality versus placebo.

Important limitation: Subjective outcome; linked modeling and validation design; replication by independent groups is needed.

PubMed ↗Our interpretation →
Human observational2022n = 470

Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics

Intervention
No intervention; baseline plasma ergothioneine
Duration
Up to 5 years

Finding: Lower baseline plasma ergothioneine was associated with poorer baseline performance and faster decline in several cognitive and functional measures.

Important limitation: Observational design cannot show that low ergothioneine caused decline or that supplementation would alter outcomes.

PubMed ↗Our interpretation →
Human pharmacokinetic2017n = See full text

Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation

Intervention
Oral pure L-ergothioneine
Duration
Short-term pharmacokinetic study

Finding: Oral ergothioneine increased plasma and whole-blood levels and had low urinary excretion. Most biomarker changes were not statistically significant.

Important limitation: Small, short study designed mainly for uptake and pharmacokinetics—not clinical outcomes.

PubMed ↗Our interpretation →
Human RCT2024n = 80

Effects of an ergothioneine-rich Pleurotus sp. on skin moisturizing functions and facial conditions: a randomized, double-blind, placebo-controlled trial

Intervention
Pleurotus tablets providing 25 mg ergothioneine/day
Duration
12 weeks

Finding: The study reported between-group differences for selected skin-moisture and imaging outcomes at certain time points.

Important limitation: Multiple outcomes and time points; mushroom matrix rather than isolated ergothioneine; some authors were employed by the mushroom producer.

PubMed ↗Our interpretation →